3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
92
Lung Neoplasms
32
NSCLC
7
Brain Neoplasms
7
Meningeal Carcinomatosis
4
Neoplasm Metastasis
3
Carcinoma, Squamous Cell
2
Bronchial Neoplasms
2
Adenocarcinoma of Lung
2
Small Cell Lung Carcinoma
1
Sexual Dysfunction, Physiological
1
Resectable Non-small Cell Lung Cancer
1
Rare Tumour
1
Prostatic Neoplasms
1
Progression Free Survival
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Non-small Cell Carcinoma
1
Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder)
1
Non-Small Cell Lung Cancer With EGFR T790M Mutation
1
Non-Small Cell Lung Cancer With EGFR Mutation
1
Non Small Cell Lung Cancer Metastatic
1
Neurocognitive
1
Neoplastic Cells, Circulating
1
Neoplasm, Residual
1
Lung Cancer Metastatic
1
Locally Advanced or Metastatic EGFRm Non-small Cell Lung Cancer (NSCLC)
1
Glioblastoma
1
Eunuchism
1
Erectile Dysfunction
1
Interventions
Etoposide
79
Carboplatin
67
Cisplatin
58
durvalumab
29
Irinotecan
29
Radiotherapy
27
atezolizumab
23
Topotecan
21
anlotinib
19
Nivolumab
15
Drug Therapy
15
Radiosurgery
14
Gemcitabine
13
apatinib
12
Paclitaxel
12
toripalimab
10
Platinum
10
Docetaxel
10
tislelizumab
9
Temozolomide
9
PM 01183
8
pembrolizumab
7
olaparib
7
Magnetic Resonance Spectroscopy
7
Ipilimumab
7
Bevacizumab
7
Albumin-Bound Paclitaxel
7
irinotecan sucrosofate
6
Counseling
6
sintilimab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Small Cell Lung Carcinoma
×
osimertinib
×
Clear all
NCT07153055
2025-12-18
LOTS
Indiana University
Phase 1/2
Not yet recruiting
16 enrolled